NASDAQ:SELB - Selecta Biosciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.63
  • Forecasted Upside: 179.54 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$2.37
▼ -0.03 (-1.25%)

This chart shows the closing price for SELB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Selecta Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SELB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SELB

Analyst Price Target is $6.63
▲ +179.54% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Selecta Biosciences in the last 3 months. The average price target is $6.63, with a high forecast of $10.00 and a low forecast of $3.50. The average price target represents a 179.54% upside from the last price of $2.37.

This chart shows the closing price for SELB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in Selecta Biosciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/3/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/1/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/30/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/30/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/29/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/26/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/25/2022

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/11/2022HC WainwrightReiterated RatingBuy$6.00Low
12/2/2021HC WainwrightReiterated RatingBuy$6.00High
11/15/2021HC WainwrightReiterated RatingBuy$6.00Low
11/1/2021Needham & Company LLCBoost Price TargetBuy$6.00 ➝ $7.00Medium
10/22/2021HC WainwrightReiterated RatingBuy$6.00Low
10/11/2021Needham & Company LLCReiterated RatingBuy$6.00Low
10/5/2021HC WainwrightReiterated RatingBuy$6.00High
9/9/2021HC WainwrightReiterated RatingBuy$6.00Low
9/2/2021HC WainwrightReiterated RatingBuy$6.00High
7/27/2021Berenberg BankReiterated RatingBuy$3.50Medium
7/27/2021HC WainwrightReiterated RatingBuy$6.00Medium
6/14/2021BTIG ResearchInitiated CoverageBuy$10.00High
5/3/2021HC WainwrightReiterated RatingBuyLow
3/12/2021William BlairUpgradeMarket Perform ➝ OutperformHigh
1/26/2021MizuhoUpgradeNeutral ➝ Buy$2.50 ➝ $8.00High
1/7/2021HC WainwrightReiterated RatingBuy$6.00N/A
10/9/2020Cantor FitzgeraldReiterated RatingOverweightLow
10/5/2020HC WainwrightLower Price TargetBuy$10.00 ➝ $6.00Low
10/1/2020MizuhoDowngradeBuy ➝ Neutral$7.00 ➝ $2.50High
10/1/2020William BlairDowngradeOutperform ➝ Market PerformHigh
8/7/2020MizuhoReiterated RatingBuy$7.00Medium
6/18/2020HC WainwrightReiterated RatingBuy$10.00High
6/18/2020Stifel NicolausReiterated RatingHoldHigh
6/18/2020Needham & Company LLCReiterated RatingBuy$5.00Medium
6/12/2020Needham & Company LLCReiterated RatingBuy$5.00High
6/12/2020Stifel NicolausDowngradeBuy ➝ Hold$4.00High
6/12/2020HC WainwrightBoost Price TargetBuy$8.00 ➝ $10.00High
6/10/2020MizuhoReiterated RatingBuy$7.00Low
5/7/2020Stifel NicolausReiterated RatingBuy$4.00High
5/7/2020Needham & Company LLCReiterated RatingBuy$5.00High
5/7/2020William BlairReiterated RatingBuyHigh
4/28/2020HC WainwrightInitiated CoverageBuy$8.00High
3/12/2020Stifel NicolausReiterated RatingBuy$4.00High
2/18/2020MizuhoReiterated RatingBuy$4.00 ➝ $7.00High
1/29/2020Cantor FitzgeraldInitiated CoverageOverweight$10.00Low
1/21/2020William BlairInitiated CoverageOutperformHigh
12/19/2019MizuhoReiterated RatingBuy$4.00Low
12/19/2019Stifel NicolausReiterated RatingBuyHigh
11/8/2019Needham & Company LLCReiterated RatingBuy$9.00Low
11/8/2019Stifel NicolausReiterated RatingBuy$6.00Low
8/11/2019MizuhoReiterated RatingBuy$4.00Medium
8/9/2019Stifel NicolausReiterated RatingBuy$6.00Low
5/10/2019MizuhoReiterated RatingBuy$4.00Low
3/15/2019Stifel NicolausReiterated RatingBuy$7.00Medium
2/5/2019Stifel NicolausSet Price TargetBuy$7.00Medium
2/4/2019MizuhoLower Price TargetBuy$4.00Low
1/28/2019Needham & Company LLCLower Price TargetBuy$12.00Low
11/9/2018UBS GroupSet Price TargetHold$6.00Medium
11/5/2018MizuhoReiterated RatingBuy$30.00Medium
10/23/2018Janney Montgomery ScottReiterated RatingBuyHigh
10/23/2018Stifel NicolausReiterated RatingBuyMedium
10/17/2018MizuhoReiterated RatingBuy$30.00High
9/14/2018Stifel NicolausInitiated CoverageBuy$24.00Low
8/9/2018MizuhoReiterated RatingBuy$30.00High
6/27/2018Janney Montgomery ScottInitiated CoverageBuy$33.00Low
4/11/2018MizuhoReiterated RatingBuy$30.00High
2/26/2018MizuhoInitiated CoverageBuy$30.00High
11/9/2017UBS GroupDowngradeBuy ➝ NeutralN/A
3/30/2017UBS GroupReiterated RatingBuy ➝ Buy$26.00N/A
3/28/2017Needham & Company LLCReiterated RatingBuy$28.00High
(Data available from 1/26/2017 forward)

News Sentiment Rating

0.41 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/30/2021
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/29/2021
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/28/2021
  • 5 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2021
  • 1 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
11/27/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/27/2021
  • 1 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/26/2022

Current Sentiment

  • 1 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Selecta Biosciences logo
Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. It produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm's proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.
Read More

Today's Range

Now: $2.37
Low: $2.30
High: $2.41

50 Day Range

MA: $3.06
Low: $2.39
High: $3.57

52 Week Range

Now: $2.37
Low: $2.19
High: $5.70

Volume

534,186 shs

Average Volume

1,046,462 shs

Market Capitalization

$276.46 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.04

Frequently Asked Questions

What sell-side analysts currently cover shares of Selecta Biosciences?

The following Wall Street analysts have issued reports on Selecta Biosciences in the last year: Berenberg Bank, BTIG Research, HC Wainwright, Mizuho, Needham & Company LLC, William Blair, and Zacks Investment Research.
View the latest analyst ratings for SELB.

What is the current price target for Selecta Biosciences?

5 Wall Street analysts have set twelve-month price targets for Selecta Biosciences in the last year. Their average twelve-month price target is $6.90, suggesting a possible upside of 191.1%. BTIG Research has the highest price target set, predicting SELB will reach $10.00 in the next twelve months. Berenberg Bank has the lowest price target set, forecasting a price of $3.50 for Selecta Biosciences in the next year.
View the latest price targets for SELB.

What is the current consensus analyst rating for Selecta Biosciences?

Selecta Biosciences currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SELB will outperform the market and that investors should add to their positions of Selecta Biosciences.
View the latest ratings for SELB.

What other companies compete with Selecta Biosciences?

How do I contact Selecta Biosciences' investor relations team?

Selecta Biosciences' physical mailing address is 65 Grove Street, Watertown MA, 02472. The company's listed phone number is (617) 923-1400 and its investor relations email address is [email protected] The official website for Selecta Biosciences is selectabio.com.